AbbVie Stock Jumps After Q2 Earnings - Here's Why
Portfolio Pulse from Vandana Singh
AbbVie Inc has reported Q2 adjusted EPS of $2.91, down 13.6% Y/Y, beating the consensus of $2.80. Overall sales decreased 4.9% Y/Y to $13.87 billion, beating the consensus of $13.52 billion. The company has raised FY23 adjusted EPS guidance from $10.57-$10.97 to $10.90-$11.10. ABBV shares are up 5.20% at $149.28.
July 27, 2023 | 3:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie's Q2 earnings and sales beat consensus estimates and the company raised its FY23 EPS guidance. This news has led to a 5.20% increase in ABBV shares.
AbbVie's better-than-expected Q2 results and raised FY23 guidance are positive signals for investors, leading to increased demand for the stock and a rise in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100